880 related articles for article (PubMed ID: 12579093)
1. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).
Nagai K; Tsuchiya R; Mori T; Tada H; Ichinose Y; Koike T; Kato H;
J Thorac Cardiovasc Surg; 2003 Feb; 125(2):254-60. PubMed ID: 12579093
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
van Meerbeeck JP; Kramer GW; Van Schil PE; Legrand C; Smit EF; Schramel F; Tjan-Heijnen VC; Biesma B; Debruyne C; van Zandwijk N; Splinter TA; Giaccone G;
J Natl Cancer Inst; 2007 Mar; 99(6):442-50. PubMed ID: 17374834
[TBL] [Abstract][Full Text] [Related]
3. Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer.
Li J; Dai CH; Yu LC; Chen P; Li XQ; Shi SB; Wu JR
Clin Lung Cancer; 2009 Sep; 10(5):353-9. PubMed ID: 19808194
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101).
Tsuchiya R; Suzuki K; Ichinose Y; Watanabe Y; Yasumitsu T; Ishizuka N; Kato H
J Thorac Cardiovasc Surg; 2005 May; 129(5):977-83. PubMed ID: 15867769
[TBL] [Abstract][Full Text] [Related]
5. [Effect of preoperative chemotherapy for bulky N2 non-small-cell lung cancer].
Togashi K; Sugawara M; Miyamura H; Sato Y; Tanabe Y; Kourakata H; Saito H; Sato K
Kyobu Geka; 1999 Oct; 52(11):915-9. PubMed ID: 10513156
[TBL] [Abstract][Full Text] [Related]
6. Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease.
Keller SM; Vangel MG; Wagner H; Schiller JH; Herskovic A; Komaki R; Marks RS; Perry MC; Livingston RB; Johnson DH;
J Thorac Cardiovasc Surg; 2004 Jul; 128(1):130-7. PubMed ID: 15224032
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group.
Keller SM; Adak S; Wagner H; Herskovic A; Komaki R; Brooks BJ; Perry MC; Livingston RB; Johnson DH
N Engl J Med; 2000 Oct; 343(17):1217-22. PubMed ID: 11071672
[TBL] [Abstract][Full Text] [Related]
8. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer.
Uy KL; Darling G; Xu W; Yi QL; De Perrot M; Pierre AF; Waddell TK; Johnston MR; Bezjak A; Shepherd FA; Keshavjee S
J Thorac Cardiovasc Surg; 2007 Jul; 134(1):188-93. PubMed ID: 17599507
[TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy in non small cell lung cancer stage IIIa-b and IV and second-line treatment.
Stathopoulos GP; Dafni UG; Malamos NA; Rigatos S; Kouvatseas G; Moschopoulos N
Anticancer Res; 1999; 19(4C):3543-8. PubMed ID: 10629650
[TBL] [Abstract][Full Text] [Related]
10. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
Imaizumi M;
Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial.
Burkes RL; Shepherd FA; Blackstein ME; Goldberg ME; Waters PF; Patterson GA; Todd T; Pearson FG; Jones D; Farooq S; McGlaughlin J; Ginsberg RJ
Lung Cancer; 2005 Jan; 47(1):103-9. PubMed ID: 15603860
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel/Platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer.
Choi IS; Oh DY; Kwon JH; Kim SI; Park SR; Bak JY; Kim JH; Kim DW; Kim YT; Kim TY; You CK; Kim YW; Heo DS; Bang YJ; Sung SW; Park CI; Kim NK
Jpn J Clin Oncol; 2005 Jan; 35(1):6-12. PubMed ID: 15681597
[TBL] [Abstract][Full Text] [Related]
14. [Neoadjuvant combined therapy in stage IIIA if non-small-cell bronchial cancer].
Thomas M; Rübe C; Semik M; Junker K; von Eiff M
Dtsch Med Wochenschr; 1997 Aug; 122(33):993-8. PubMed ID: 9296933
[TBL] [Abstract][Full Text] [Related]
15. The evolution of treatment outcomes for resected stage IIIA non-small cell lung cancer over 16 years at a single institution.
Martin LW; Correa AM; Hofstetter W; Hong WK; Komaki R; Putnam JB; Rice DC; Smythe WR; Swisher SG; Vaporciyan AA; Walsh GL; Roth JA
J Thorac Cardiovasc Surg; 2005 Dec; 130(6):1601-10. PubMed ID: 16308005
[TBL] [Abstract][Full Text] [Related]
16. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.
Rosell R; Gómez-Codina J; Camps C; Maestre J; Padille J; Cantó A; Mate JL; Li S; Roig J; Olazábal A
N Engl J Med; 1994 Jan; 330(3):153-8. PubMed ID: 8043059
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer.
Westeel V; Quoix E; Moro-Sibilot D; Mercier M; Breton JL; Debieuvre D; Richard P; Haller MA; Milleron B; Herman D; Level MC; Lebas FX; Puyraveau M; Depierre A;
J Natl Cancer Inst; 2005 Apr; 97(7):499-506. PubMed ID: 15812075
[TBL] [Abstract][Full Text] [Related]
19. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer.
Higgins K; Chino JP; Marks LB; Ready N; D'Amico TA; Clough RW; Kelsey CR
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1462-7. PubMed ID: 19467798
[TBL] [Abstract][Full Text] [Related]
20. Persistent N2 disease after induction therapy does not jeopardize early and medium term outcomes of pneumonectomy.
Mansour Z; Kochetkova EA; Santelmo N; Ducrocq X; Quoix E; Wihlm JM; Massard G
Ann Thorac Surg; 2008 Jul; 86(1):228-33. PubMed ID: 18573428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
